Active TB · HIV‐negative people at risk of TB infection1
It is very uncertain whether rifampicin changes active TB compared with isoniazid (very low certainty).
1 finding from 1 review
Adherence6 · HIV‐negative people at risk of TB infection1
Rifampicin probably leads to higher adherence6 compared with isoniazid (moderate certainty).
1 finding from 1 review
Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1
It is very uncertain whether rifampicin changes treatment‐limiting adverse events compared with isoniazid (very low certainty).
1 finding from 1 review
Hepatotoxicity:13 Grade 3 and 4 toxicity · HIV‐negative people at risk of TB infection1
Rifampicin probably leads to lower hepatotoxicity:13 Grade 3 and 4 toxicity compared with isoniazid (moderate certainty).
1 finding from 1 review
Time‐to‐resolution: achieving PASI 90 to 100 or PGA 0 to 1 · guttate psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse events and severe adverse events · guttate psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants achieving clear or almost clear skin (PASI 90 to 100 or PGA 0 to 1) · guttate psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants achieving PASI 75 or PGA 1 to 2 · guttate psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse · guttate psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment failure · adults with scrub typhus
1 finding from 1 review
Resolution of fever within 48 hours · adults with scrub typhus
It is very uncertain whether rifampicin changes resolution of fever within 48 hours compared with doxycycline (very low certainty).
1 finding from 1 review
Resolution of fever within 5 days · adults with scrub typhus
The review found no eligible studies for this question.
1 finding from 1 review
Time to defervescence · adults with scrub typhus
1 finding from 1 review
Serious adverse events · adults with scrub typhus
The review found no eligible studies for this question.
1 finding from 1 review
total treatment failure · patients with human Brucellosis
Doxycycline+Rifampicin showed no clear difference in total treatment failure compared with quinolones+Rifampicin (moderate certainty).
1 finding from 1 review
Minor adverse drug reactions · patients with human Brucellosis
Doxycycline+Rifampicin showed no clear difference in minor adverse drug reactions compared with quinolones+Rifampicin (low certainty).
1 finding from 1 review
Curea · people with Buruli ulcer, early lesions measuring less than 10 cm in diameter, aged 5 years or older
Rifampicin with clarithromycin showed no clear difference in curea compared with rifampicin with streptomycin (low certainty).
1 finding from 1 review
Active TB · HIV‐negative people at risk of TB infection1
It is very uncertain whether rifampicin plus isoniazid changes active TB compared with isoniazid (very low certainty).
1 finding from 1 review
Adherence · HIV‐negative people at risk of TB infection1
Rifampicin plus isoniazid showed no clear difference in adherence compared with isoniazid (high certainty).
1 finding from 1 review
Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1
Rifampicin plus isoniazid showed no clear difference in treatment‐limiting adverse events compared with isoniazid (low certainty).
1 finding from 1 review